Given the increasing evidence around de-escalating axillary surgery, the Choosing Wisely statement (48) declared that SLNB is not required for women ≥ 70 years with clinically node-negative (cN0) breast cancer, which is hormone receptor-positive and HER2-negative if they are adjuvantly treated with hormonal therapy. The gene discussed is ERBB2; the disease is breast carcinoma.